Studies have confirmed that activation of receptors for advanced glycation end products (RAGEs) in other diseases, such as liver ischemia/reperfusion injury and colon cancer, can stimulate the transcription of the Egr1 and AP-1 families [61–64]. Here, FOS is linked to malignant colon neoplasm.